<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03136237</url>
  </required_header>
  <id_info>
    <org_study_id>BCX7353-105</org_study_id>
    <nct_id>NCT03136237</nct_id>
  </id_info>
  <brief_title>A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Effect of BCX7353 on the Single Dose Pharmacokinetics of the P-gp Substrate Digoxin and the BCRP Substrate Rosuvastatin and the Effect of the P-gp Inhibitor Cyclosporine on the Single Dose Pharmacokinetics of BCX7353</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, three part study to evaluate the effect of BCX7353 on drug
      transporters as well as the effect of an inhibitor of drug transport on BCX7353.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, open-label, fixed-sequence, drug interaction study to evaluate the
      effect of BCX7353 on the pharmacokinetics of the P-gp substrate digoxin and the BCRP
      substrate rosuvastatin, as well as the effect of the P-gp inhibitor cyclosporine on the
      pharmacokinetics of BCX7353.

      It is planned that 54 subjects will be enrolled into 3 cohorts of 18 subjects each. Cohort 1
      will evaluate the effects of multiple doses of BCX7353 on single-dose pharmacokinetics of
      digoxin. Cohort 2 will evaluate the effect of multiple doses of BCX7353 on the
      pharmacokinetics of rosuvastatin. Cohort 3 will evaluate the effect of a single dose of
      cyclosporine on the pharmacokinetics of BCX7353. Cohorts may be dosed in parallel or in any
      order.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 17, 2017</start_date>
  <completion_date type="Actual">August 15, 2017</completion_date>
  <primary_completion_date type="Actual">August 15, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>3 parallel treatment assessments</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of probe substrate</measure>
    <time_frame>plasma pharmacokinetic parameters are based on blood sampling over a 48 - 72 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of probe substrate</measure>
    <time_frame>plasma pharmacokinetic parameters are based on blood sampling over a 48 - 72 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of probe substrate</measure>
    <time_frame>plasma pharmacokinetic parameters are based on blood sampling over a 48 - 72 hour period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>absolute and change from baseline through end of study, approximately 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory analyses</measure>
    <time_frame>absolute and change from baseline through end of study, approximately 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vital signs</measure>
    <time_frame>absolute and change from baseline through end of study, approximately 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical examination findings</measure>
    <time_frame>absolute and change from baseline through end of study, approximately 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>electrocardiograms</measure>
    <time_frame>absolute and change from baseline throughend of study, approximately 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Digoxin 0.25 mg oral dose Day 11-18: BCX7353 350 mg oral dose Day 19: Digoxin 0.25 mg oral dose and BCX7353 350 mg oral dose Day 20-21: BCX7353 350 mg oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Rosuvastatin 10 mg oral dose Day 7-14: BCX7353 350 mg oral dose Day 15: Rosuvastatin 10 mg oral dose and BCX7353 350 mg oral dose Day 16: BCX7353 350 mg oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: BCX7353 350 mg oral dose Day 14: single oral dose of Cyclosporine 600 mg and BCX7353 350 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCX7353</intervention_name>
    <description>Day 11-18 for Cohort 1, Day 7-14 for Cohort 2, Day 1 for Cohort 3</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>Day 1 of Cohort 1</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCX7353 + digoxin</intervention_name>
    <description>Day 19 of Cohort 1</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Day 1 of Cohort 2</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin + BCX7353</intervention_name>
    <description>Day 15 of Cohort 1</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine + BCX7353</intervention_name>
    <description>Day 14 of Cohort 3</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  written informed consent

          -  acceptable birth control measures for male subjects and women of childbearing
             potential

          -  creatinine clearance of at least 80 mL/min by Cockcroft-Gault equation

          -  complies with all required study procedures and restrictions

        Key Exclusion Criteria:

          -  clinically significant medical history, current medical or psychiatric condition

          -  clinically significant ECG finding, vital sign measurement or laboratory/urinalysis
             abnormality at screening or baseline

          -  current use, or use of any prescribed or over the counter medication, vitamins or
             herbal products within 14 days of Day 1

          -  use of medication that is known to inhibit or induce metabolic enzymes or transporters
             within 30 days of dosing

          -  participation in any other investigational drug study within 90 days of screening

          -  recent or current history of alcohol or drug abuse

          -  regular recent use of tobacco or nicotine products

          -  positive serology for HBV, HCV, or HIV

          -  pregnant or nursing

          -  donation or loss of greater than 400 mL of blood within the previous 3 months

          -  history of severe hypersensitivity to any medicinal product

          -  for subjects enrolled in cohort 1, current use of antibiotics or probiotics, or use
             within 6 months prior to Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Firas Almazedi, MBChB, Msc, CPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance CRU</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

